Monoaminergic Dysregulation in Major Depressive Disorder
Objectives:
- Understand how the dysregulation of the noradrenergic system contributes to the heterogeneous presentation of MDD symptoms
- Understand why, in addition to serotonin (5-HT) and dopamine (DA), noradrenaline (NA) dysregulation may also contribute to unresolved symptoms in MDD
- Discuss the role of adrenoreceptors (ARs) on neuronal activity and how ARs can help modulate symptoms caused by noradrenergic system dysfunction
- Learn how adjunctive atypical antipsychotics (AAPs) may address MDD symptoms by modulating dysregulation of the NA system, in addition to DA and 5-HT
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Request this program for your region or organization today! This live (online or in-person) presentation, and others like it, are available for free for Members. View our complete listing of presentations and programs by visiting our Custom Program Request page.
Request Program